Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Mark Yates

A/Prof Mark Yates

Dementia & Chronic Disease – Practical Advice

Dr Julia Crawford

Dr Julia Crawford

Head and Neck Lumps

A/Prof Nicole Goh

A/Prof Nicole Goh

The NLCSP – Incidental Chest Findings – What Now? – A Focus on Interstitial Lung Abnormalities

A/Prof Martin MacDonald

A/Prof Martin MacDonald

Why are LAMAs Useful in Asthma Management

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022